Related Experiment Video

Updated: Jun 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

E S Antonarakis1, A J Armstrong

  • 1Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA. eantona1@jhmi.edu

Prostate Cancer and Prostatic Diseases
|May 18, 2011
PubMed

Insights

New treatments for metastatic castration-resistant prostate cancer (CRPC) show promise but offer transient benefits. This review explores emerging therapies in phase II/III trials to improve patient survival times.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (CRPC) has limited treatment options with transient clinical benefits.
  • Current systemic therapies for CRPC offer limited survival advantages, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review emerging therapeutic paradigms and research strategies for metastatic CRPC.
  • To discuss novel agents in phase II and III clinical testing for advanced prostate cancer.
  • To evaluate how new therapies may complement existing treatment options for CRPC.

Main Methods:

  • Literature review of emerging treatments for metastatic CRPC.
  • Analysis of ongoing phase II and III clinical trials.
  • Discussion of novel hormonal, immunomodulatory, antiangiogenic, epigenetic, and cell survival pathway inhibitors.

Main Results:

  • Several novel agents targeting various pathways are under investigation.
  • Emerging therapies aim to overcome treatment resistance and prolong survival in CRPC.
  • Combinatorial approaches are being explored to enhance clinical benefit.

Conclusions:

  • Emerging therapies hold potential to improve outcomes for men with metastatic CRPC.
  • Further research and clinical trials are crucial to validate the efficacy of novel agents.
  • Personalized treatment strategies may enhance the effectiveness of future CRPC therapies.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...